A retrospective study on tolvaptan prescription in clinical practice in patients with syndrome of inappropriate secretion of antidiuretic hormone (SIADH) using the Japanese claims database
We aimed to survey the status of tolvaptan administration in routine clinical practice since the approval of a novel indication for treating syndrome of inappropriate secretion of antidiuretic hormone (SIADH) in Japan. Data from a population of 3,152 patients aged ≥18 years and diagnosed with SIADH...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
The Japan Endocrine Society
2023-12-01
|
| Series: | Endocrine Journal |
| Subjects: | |
| Online Access: | https://www.jstage.jst.go.jp/article/endocrj/70/12/70_EJ23-0256/_html/-char/en |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832591719161397248 |
|---|---|
| author | Daisuke Hagiwara Miyuki Matsukawa Junko Tasaki Yumiko Nakamura Hiroshi Arima |
| author_facet | Daisuke Hagiwara Miyuki Matsukawa Junko Tasaki Yumiko Nakamura Hiroshi Arima |
| author_sort | Daisuke Hagiwara |
| collection | DOAJ |
| description | We aimed to survey the status of tolvaptan administration in routine clinical practice since the approval of a novel indication for treating syndrome of inappropriate secretion of antidiuretic hormone (SIADH) in Japan. Data from a population of 3,152 patients aged ≥18 years and diagnosed with SIADH between July 1, 2020 and June 30, 2021 were extracted from a Japanese database. Tolvaptan was administered to 586 patients while 2,566 patients were followed up without tolvaptan. In the tolvaptan-treated group, the standard initial doses were 3.75 mg and 7.5 mg in 290 (49.5%) and 250 (42.7%) patients, respectively. The dose was increased in 112 (38.6%) and 71 (28.4%) and decreased in 8 (2.8%) and 46 (18.4%) of patients with 3.75 and 7.5 mg initial doses, respectively. Of the total 586 SIADH patients treated with tolvaptan, serum sodium concentrations were analyzed in 60 patients. In both treatment groups of 3.75 and 7.5 mg initial doses, the serum sodium concentration was elevated from the second day of treatment and reached 135 mEq/L on the fourth day, which was maintained for 2 weeks. Rapid correction of hyponatremia (>10 mEq/L increase in serum sodium concentration over 1 day or >18 mEq/L increase over 2 days) occurred in 26.7% patients with a 7.5 mg initial dose (4 of 15 patients) but not in the patients with a 3.75 mg initial dose (n = 16), suggesting that an initial dose of 3.75 mg of tolvaptan may be a better choice for the safe and proper correction of hyponatremia. |
| format | Article |
| id | doaj-art-9b9939d10dd6443290df6890d16e470e |
| institution | Kabale University |
| issn | 1348-4540 |
| language | English |
| publishDate | 2023-12-01 |
| publisher | The Japan Endocrine Society |
| record_format | Article |
| series | Endocrine Journal |
| spelling | doaj-art-9b9939d10dd6443290df6890d16e470e2025-01-22T06:25:10ZengThe Japan Endocrine SocietyEndocrine Journal1348-45402023-12-0170121195120510.1507/endocrj.EJ23-0256endocrjA retrospective study on tolvaptan prescription in clinical practice in patients with syndrome of inappropriate secretion of antidiuretic hormone (SIADH) using the Japanese claims databaseDaisuke Hagiwara0Miyuki Matsukawa1Junko Tasaki2Yumiko Nakamura3Hiroshi Arima4Department of Endocrinology and Diabetes, Nagoya University Graduate School of Medicine, Nagoya 466-8550, JapanMedical Affairs, Otsuka Pharmaceutical Co., Ltd., Tokyo 101-8535, JapanMedical Affairs, Otsuka Pharmaceutical Co., Ltd., Tokyo 101-8535, JapanMedical Affairs, Otsuka Pharmaceutical Co., Ltd., Tokyo 101-8535, JapanDepartment of Endocrinology and Diabetes, Nagoya University Graduate School of Medicine, Nagoya 466-8550, JapanWe aimed to survey the status of tolvaptan administration in routine clinical practice since the approval of a novel indication for treating syndrome of inappropriate secretion of antidiuretic hormone (SIADH) in Japan. Data from a population of 3,152 patients aged ≥18 years and diagnosed with SIADH between July 1, 2020 and June 30, 2021 were extracted from a Japanese database. Tolvaptan was administered to 586 patients while 2,566 patients were followed up without tolvaptan. In the tolvaptan-treated group, the standard initial doses were 3.75 mg and 7.5 mg in 290 (49.5%) and 250 (42.7%) patients, respectively. The dose was increased in 112 (38.6%) and 71 (28.4%) and decreased in 8 (2.8%) and 46 (18.4%) of patients with 3.75 and 7.5 mg initial doses, respectively. Of the total 586 SIADH patients treated with tolvaptan, serum sodium concentrations were analyzed in 60 patients. In both treatment groups of 3.75 and 7.5 mg initial doses, the serum sodium concentration was elevated from the second day of treatment and reached 135 mEq/L on the fourth day, which was maintained for 2 weeks. Rapid correction of hyponatremia (>10 mEq/L increase in serum sodium concentration over 1 day or >18 mEq/L increase over 2 days) occurred in 26.7% patients with a 7.5 mg initial dose (4 of 15 patients) but not in the patients with a 3.75 mg initial dose (n = 16), suggesting that an initial dose of 3.75 mg of tolvaptan may be a better choice for the safe and proper correction of hyponatremia.https://www.jstage.jst.go.jp/article/endocrj/70/12/70_EJ23-0256/_html/-char/entolvaptansyndrome of inappropriate secretion of antidiuretic hormonehyponatremiaosmotic demyelinating syndrome |
| spellingShingle | Daisuke Hagiwara Miyuki Matsukawa Junko Tasaki Yumiko Nakamura Hiroshi Arima A retrospective study on tolvaptan prescription in clinical practice in patients with syndrome of inappropriate secretion of antidiuretic hormone (SIADH) using the Japanese claims database Endocrine Journal tolvaptan syndrome of inappropriate secretion of antidiuretic hormone hyponatremia osmotic demyelinating syndrome |
| title | A retrospective study on tolvaptan prescription in clinical practice in patients with syndrome of inappropriate secretion of antidiuretic hormone (SIADH) using the Japanese claims database |
| title_full | A retrospective study on tolvaptan prescription in clinical practice in patients with syndrome of inappropriate secretion of antidiuretic hormone (SIADH) using the Japanese claims database |
| title_fullStr | A retrospective study on tolvaptan prescription in clinical practice in patients with syndrome of inappropriate secretion of antidiuretic hormone (SIADH) using the Japanese claims database |
| title_full_unstemmed | A retrospective study on tolvaptan prescription in clinical practice in patients with syndrome of inappropriate secretion of antidiuretic hormone (SIADH) using the Japanese claims database |
| title_short | A retrospective study on tolvaptan prescription in clinical practice in patients with syndrome of inappropriate secretion of antidiuretic hormone (SIADH) using the Japanese claims database |
| title_sort | retrospective study on tolvaptan prescription in clinical practice in patients with syndrome of inappropriate secretion of antidiuretic hormone siadh using the japanese claims database |
| topic | tolvaptan syndrome of inappropriate secretion of antidiuretic hormone hyponatremia osmotic demyelinating syndrome |
| url | https://www.jstage.jst.go.jp/article/endocrj/70/12/70_EJ23-0256/_html/-char/en |
| work_keys_str_mv | AT daisukehagiwara aretrospectivestudyontolvaptanprescriptioninclinicalpracticeinpatientswithsyndromeofinappropriatesecretionofantidiuretichormonesiadhusingthejapaneseclaimsdatabase AT miyukimatsukawa aretrospectivestudyontolvaptanprescriptioninclinicalpracticeinpatientswithsyndromeofinappropriatesecretionofantidiuretichormonesiadhusingthejapaneseclaimsdatabase AT junkotasaki aretrospectivestudyontolvaptanprescriptioninclinicalpracticeinpatientswithsyndromeofinappropriatesecretionofantidiuretichormonesiadhusingthejapaneseclaimsdatabase AT yumikonakamura aretrospectivestudyontolvaptanprescriptioninclinicalpracticeinpatientswithsyndromeofinappropriatesecretionofantidiuretichormonesiadhusingthejapaneseclaimsdatabase AT hiroshiarima aretrospectivestudyontolvaptanprescriptioninclinicalpracticeinpatientswithsyndromeofinappropriatesecretionofantidiuretichormonesiadhusingthejapaneseclaimsdatabase AT daisukehagiwara retrospectivestudyontolvaptanprescriptioninclinicalpracticeinpatientswithsyndromeofinappropriatesecretionofantidiuretichormonesiadhusingthejapaneseclaimsdatabase AT miyukimatsukawa retrospectivestudyontolvaptanprescriptioninclinicalpracticeinpatientswithsyndromeofinappropriatesecretionofantidiuretichormonesiadhusingthejapaneseclaimsdatabase AT junkotasaki retrospectivestudyontolvaptanprescriptioninclinicalpracticeinpatientswithsyndromeofinappropriatesecretionofantidiuretichormonesiadhusingthejapaneseclaimsdatabase AT yumikonakamura retrospectivestudyontolvaptanprescriptioninclinicalpracticeinpatientswithsyndromeofinappropriatesecretionofantidiuretichormonesiadhusingthejapaneseclaimsdatabase AT hiroshiarima retrospectivestudyontolvaptanprescriptioninclinicalpracticeinpatientswithsyndromeofinappropriatesecretionofantidiuretichormonesiadhusingthejapaneseclaimsdatabase |